Life Science REIT (LON:LABS – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Berenberg Bank in a report released on Thursday, MarketBeat.com reports. They currently have a GBX 57 ($0.76) price target on the stock. Berenberg Bank’s price target would indicate a potential upside of 46.15% from the stock’s current price.
Several other equities analysts have also recently commented on LABS. Shore Capital reiterated a “buy” rating on shares of Life Science REIT in a research note on Thursday, September 26th. Jefferies Financial Group cut their target price on Life Science REIT from GBX 45 ($0.60) to GBX 36 ($0.48) and set a “hold” rating for the company in a research report on Friday, August 30th.
Get Our Latest Stock Analysis on LABS
Life Science REIT Stock Down 2.5 %
Featured Articles
- Five stocks we like better than Life Science REIT
- 5 Top Rated Dividend Stocks to Consider
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What Are Dividend Achievers? An Introduction
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- What does consumer price index measure?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Life Science REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Life Science REIT and related companies with MarketBeat.com's FREE daily email newsletter.